NEW YORK (GenomeWeb) – Roche Diagnostic Canada said on Tuesday that Health Canada has approved the Cobas EGFR Mutation Test v2 for marketing in that country.
The oncology assay is the first from Roche using either plasma or tumor tissue samples and identifies 42 mutations in the epidermal growth factor receptor gene, which the firm said is the most of any in vitro diagnostic on the market. It added that the assay can also be used to help select appropriate patients with non-small cell lung cancer for therapy with an EGFR tyrosine kinase inhibitor.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?